ANTISENSE TECHNOLOGY

ANTISENSE TECHNOLOGY

An antisense oligonucleotide (ASO) is a single-stranded deoxyribonucleotide, which is complementary to the mRNA target. The goal of the antisense approach is the downregulation of a molecular target, usually achieved by induction of RNase H endonuclease activity that cleaves the RNA-DNA heteroduplex with a significant reduction of the target gene translation . Other ASO-driven mechanisms include inhibition of 5′ cap formation, alteration of splicing process (splice-switching), and steric hindrance of ribosomal activity .

Drug

# There are six FDA-approved drugs based on oligonucleotide therapy:-

(1) fomivirsen for treatment of CMV retinitis in AIDS patients.

(2) mipomersen for treatment of familial hypercholesterolemia.

(3) Defibrotide for treatment of veno-occlusive disease in the liver.

(4) eteplirsen for the treatment of Duchenne muscular dystrophy.

(5) pegaptanib for the treatment of neovascular age-related macular degeneration.

(6) nusinersen for the management of spinal muscular atrophy.



Comments

Popular posts from this blog

article review on tocilizumab production

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

article review on adalimumab production